Optical Coherence Tomography Features Predicting the Response of Diabetic Macular Oedema to Treatment with Fluocinolne Acetonide Intravitreal Implant, a Cohort Study.

Abstract

Purpose We aimed to list the OCT features associated with good response to treatment with Iluvien (fluocinolone acetonide). Among these features we looked to describe the commonest OCT signs in patients with diabetic macular oedema and furthermore to correlate the change in visual acuity with the OCT changes. Methods This is a retrospective observational study including 17 eyes of 14 patients who were treated fluocinolone acetonide 0.19 mg intravitreal implant as a second line of treatment. OCT scans were obtained and LogMAR visual acuity data were collected on regular visits for 12 months before and 12 months after receiving the fluocinolone acetonide implant. Results At the end of the 12 months post-fluocinolone acetonide follow up period, there was a mean reduction of the CMT by 43.9 µm from the baseline (visit -12 months) and 158 µm from the time of treatment with fluocinolone acetonide, these are equivalent to 12% and 42%, respectively. The change in visual acuity was equivalent to +5 ETDRS letters compared to the baseline (visit -12 months) and +7.2 ETDRS letters compared to the time of treatment with fluocinolone acetonide. We observed a significant reduction in inflammatory features seen in that time. Conclusions We showed that fluocinolone acetonide significantly reduced macular inflammatory signs, particularly the proportion of eyes with disorganization of retinal inner layers (DRIL) and hyper reflective foci at 12 months post-treatment. CE Notification: This article is available as a COPE accredited CE course. You may take this course for 1-hour credit. Read the article and take the qualifying test to earn your credit. Click here to Enroll (https://www.crojournal.com/oct-features-predicting-the-response-of-diabetic-macular-oedema-to-treatment-with-fluocinolone-acetonide-intravitreal-implant)